vaccine

The coronavirus vaccine developed by Pfizer and BioNTech is more than 90 percent effective, the companies said Monday in a major milestone for the fight against the deadly global pandemic. The

The prediction was the latest suggestion from a major drugmaker that the race to produce a vaccine for the deadly COVID-19 bug could reach a significant milestone in the coming months.

Biotech firm Moderna expects to have about 20 million doses of its experimental coronavirus vaccine ready to ship in the US by the end of the year. The Massachusetts-based drug developer will be

At the forefront of coronavirus vaccine trials, Jair Bolsonaro's Brazil is paradoxically in total confusion regarding the immunization of its own population, at stake in an ideological war.

After AstraZaneca, it is the turn of another large laboratory, Johnson & Johnson, to stop its clinical trials, due to an unexplained disease contracted by a patient during the test. In a statement, the American lab said the participant's disease was being analyzed and assessed by an external panel as well as by doctors in the group. Bad timing: despite good financial results for the third quarter published today, the stock market began to heckle the title.

Biotech firm Moderna expects to know by November whether its coronavirus vaccine is effective at warding off the deadly disease, CEO Stephane Bancel said Thursday. Massachusetts-based Moderna says it has enrolled 25,296 people in the late-stage clinical trial of its COVID-19 vaccine that kicked off in July, one of three such studies currently underway in …

Bill Gates says Pfizer has the best chance of seeking emergency approval for a coronavirus vaccine by next month even though he thinks such an aggressive timeline is unlikely. “The only vaccine that if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer,” the billionaire tech tycoon-turned-philanthropist …

Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said. There’s a “more than 60 percent” chance that the drugmaker’s clinical research will produce results by the end of October showing whether or not the shot works, Bourla said in a Sunday TV …

AstraZeneca’s coronavirus vaccine could still be ready this year even though it had to halt a key clinical study after a participant got sick, CEO Pascal Soriot said Thursday. The British pharmaceutical firm should know by the end of 2020 whether the vaccine protects patients from the virus if it’s able to resume the study …

Nine drugmakers pledged Tuesday to make safety their top priority as they race to develop a vaccine for the deadly coronavirus — vowing they would not seek emergency authorization before large-scale Phase 3 clinical trials are completed. The biopharma firms said in a joint statement that they would follow “high ethical standards and sound scientific …